Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Confirm persistent airflow obstruction in the correct clinical context, describe disease impact beyond FEV1, and identify alternative diagnoses, alpha-1 antitrypsin deficiency and complications that change management.
COPD is persistent, usually progressive airflow obstruction associated with an abnormal inflammatory response to inhaled exposures. Diagnosis requires both the clinical syndrome and objective post-bronchodilator obstruction; radiographic emphysema and chronic bronchitis can exist with different degrees of spirometric impairment.
Staging serves different purposes. FEV1 describes airflow impairment, the MRC scale describes activity-related breathlessness, and exacerbation history describes future attack risk. Management decisions draw on all three plus eosinophilic/asthmatic features, comorbidity and patient goals.
Diagnostic review is essential when the pattern is atypical: marked day-to-day variability, onset under 35, no exposure, haemoptysis, clubbing, weight loss, rapid decline or symptoms disproportionate to spirometry.
Long-term active smoking is the dominant UK exposure, with risk shaped by intensity, duration, early-life lung development and individual susceptibility.
Dusts, fumes, biomass smoke and air pollution contribute cumulative airway and alveolar injury, particularly when combined with tobacco exposure.
Inherited severe deficiency permits unopposed protease activity and early emphysema, especially with smoking, and should be considered in a compatible phenotype or family history.
Prematurity, childhood respiratory disease and disadvantage may limit peak attained lung function, allowing persistent obstruction to emerge without unusually rapid adult decline.
Repeated inhaled injury recruits inflammatory cells, thickens small-airway walls and increases mucus production, progressively narrowing conducting airways.
Alveolar wall destruction reduces the radial traction that holds small airways open, causing expiratory collapse and gas trapping.
Incomplete emptying raises resting lung volume and flattens the diaphragm, increasing the work of breathing and limiting inspiratory reserve during exercise.
Uneven obstruction and emphysematous capillary loss create ventilation-perfusion mismatch, leading to hypoxaemia and, in advanced ventilatory failure, carbon dioxide retention.
Age over 35, cumulative tobacco/occupational exposure, progressive exertional dyspnoea, chronic cough/sputum, wheeze and winter exacerbations, with persistent post-bronchodilator obstruction.
Productive cough for at least 3 months in each of 2 consecutive years after excluding other causes. It can coexist with emphysema and signals exacerbation/mucus burden but is not synonymous with obstruction.
Hyperinflation, reduced breath sounds, low BMI or reduced gas transfer, with low-attenuation change on CT when imaged. Consider alpha-1 antitrypsin deficiency if young, minimally exposed or basal predominant.
Previous secure asthma/atopy, substantial FEV1 variation (for example at least 400 mL), or higher eosinophils may alter inhaler choice. Do not use a single small reversibility result to invent an overlap label.
Marked symptom variability, atopy and objective variability or reversibility favour asthma, whereas COPD obstruction is persistent; neither a single bronchodilator result nor age alone decides.
Large-volume purulent sputum, recurrent infection and bronchial dilatation on CT point towards bronchiectasis, which may coexist with COPD.
Orthopnoea, oedema, cardiac signs and congestion on imaging support heart failure, while spirometry should be interpreted after acute fluid overload settles.
Fine crackles, clubbing, restrictive physiology and interstitial change on imaging argue for parenchymal fibrosis rather than primary obstructive airway disease.
Haemoptysis, weight loss, focal chest signs or a new radiographic lesion require investigation for malignancy rather than attribution to chronic COPD symptoms.
Clubbing, focal signs, haemoptysis, very large sputum volume, systemic features, rapid decline or disproportionate hypoxaemia suggests cancer, bronchiectasis, ILD, TB, heart failure or pulmonary vascular disease.
Infective or environmental insults can abruptly worsen airway inflammation, symptoms and gas exchange, accelerating functional decline and prompting hospital admission.
Advanced ventilation-perfusion mismatch and pump overload cause chronic hypoxaemia, sometimes with hypercapnia, pulmonary vascular stress and vulnerability to acute decompensation.
Chronic hypoxic vasoconstriction, vascular remodelling and loss of capillary bed can raise pulmonary pressure and eventually strain the right ventricle.
Breathlessness, systemic inflammation and inactivity drive skeletal-muscle loss, reduced exercise capacity and poorer resilience to further illness.
Rupture of emphysematous bullae can produce secondary spontaneous pneumothorax, causing disproportionate physiological compromise in limited respiratory reserve.
Airflow impairment predicts some outcomes but activity limitation is also shaped by hyperinflation, muscle deconditioning, cardiac disease, anxiety and anaemia.
FEV1/FVC naturally falls with age. A value just below 0.70 in an asymptomatic older non-smoker deserves review, not automatic lifelong COPD labeling.
Look for lung cancer, bronchiectasis, ILD or another cause rather than attributing it to emphysema.
Some COPD varies and some treated asthma is fixed. Use longitudinal symptoms, exposure, atopy/eosinophils and magnitude/history—not one bronchodilator test.
Smoking treatment, pulmonary rehabilitation, vaccination and cardiovascular risk care often produce more benefit than arguing over a narrow FEV1 category.
Diagnosing COPD from symptoms, CXR hyperinflation or pre-bronchodilator spirometry alone.
Using FEV1 stage as the whole severity assessment.
Ignoring LLN and clinical context around a borderline ratio.
Attributing clubbing, haemoptysis or weight loss to uncomplicated COPD.
Missing alpha-1 antitrypsin deficiency in a young or minimally exposed patient.
Assuming every acute breathlessness episode is a COPD exacerbation.
Your practice draft is saved in this browser.
A 62-year-old with 40 pack-years has chronic exertional breathlessness and sputum. Which finding is required to objectively confirm persistent airflow obstruction under NICE guidance?
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes
Individualise to cigarettes/day, time to first cigarette, pregnancy and cardiovascular context; avoid smoking while using more nicotine than intended and teach correct gum/lozenge technique. Link to behavioural support.
Rising use signals poor control or another diagnosis. Tremor, tachycardia and hypokalaemia can occur; ensure technique and do not use response as diagnostic proof.